Litigation Details for PAR PHARMACEUTICAL, INC. v. QUVA PHARMA, INC. (D.N.J. 2017)
✉ Email this page to a colleague
PAR PHARMACEUTICAL, INC. v. QUVA PHARMA, INC. (D.N.J. 2017)
| Docket | ⤷ Subscribe | Date Filed | 2017-08-14 |
| Court | District Court, D. New Jersey | Date Terminated | |
| Cause | 18:1836(b) Civil Action to Protect Trade Secrets | Assigned To | Brian R. Martinotti |
| Jury Demand | Plaintiff | Referred To | Douglas Arpert |
| Patents | 9,375,478; 9,687,526; 9,744,209; 9,744,239; 9,750,785 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in PAR PHARMACEUTICAL, INC. v. QUVA PHARMA, INC.
The small molecule drug covered by the patents cited in this case is ⤷ Subscribe .
Details for PAR PHARMACEUTICAL, INC. v. QUVA PHARMA, INC. (D.N.J. 2017)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2018-02-08 | 136 | are: (1) U.S. Patent No. 9,375,478; (2) U.S. Patent No. 9,687,526; (3) U.S. Patent No. 9,744,239; (4) …any of five patents Par purports to own in connection with Vasostrict®. 5 5 The patents at issue are…) U.S. Patent No. 9,744,209; and (5) U.S. Patent No. 9,750,785. | External link to document | |
| 2018-06-18 | 249 | Brief | are listed below: • U.S. Patent No. 9,375,478 (“the ’478 patent”), which issued on June 28, …and Par itself. By definition, Par’s own patents 1 and patent applications covering its product are the… at least five patents relating to its vasopressin injection product. These patents, with their corresponding…previously published; • U.S. Patent No. 9,687,526 (“the ’526 patent”), which issued on June 27, …February 9, 2017; • U.S. Patent No. 9,744,239 (“the ’239 patent”), which issued on August 29, | External link to document |
| 2018-06-18 | 251 | Brief | consist of information in Par’s own patent and published patent application, as well general knowledge…published U.S. Patent Application No. 2017/0290881 (the “’881 publication”), Par’s U.S. Patent No. 9,375,478…which is disclosed in an issued patent or in a published patent application, is not secret and thus…9,375,478 (the “’478 patent”), and other public information disclose a majority of Par’s vasopressin …regarding vasopressin, and possibly to later bring patent litigation against QuVa. (Ex. 349 at 2-3, 19 | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
